Determination of distribution coefficients of mercury and gold on selected extraction chromatographic resins - towards an improved separation method of mercury-197 from proton-irradiated gold targets.

Radioisotope mercury-197g (197gHg, half-life: 64.14 h) along with its metastable isomer (197mHg, half-life: 23.8 h) are potential candidates for targeted Meitner-Auger electron therapy due to their suitable decay properties. Their production can be achieved via proton irradiation of a natural gold target, but the number of studies surrounding their separation from an irradiated gold target is limited. This study focuses on the determination of distribution coefficients (Kd) of gold (III) and mercury (II) on seven extraction chromatographic resins. Mercury Kd were measured by means of radiotracers and Inductively Coupled Plasma Mass Spectrometry (ICP_MS); values obtained from the two methods were generally in good agreement. These results can provide insight on Hg and Au chemistry and aid in the design of improved separation system(s).

[1]  J. Despotopulos,et al.  Extraction of gold, mercury, and lead with TEVA resin from HCl and HNO3 , 2022, Journal of Radioanalytical and Nuclear Chemistry.

[2]  S. Lahiri,et al.  Separation of no-carrier-added 195,195m,197mHg from proton irradiated Au target by TK200 and DGA-N resins , 2021, Journal of Radioanalytical and Nuclear Chemistry.

[3]  J. Despotopulos,et al.  Rapid isolation of 197m,gHg from proton irradiated Au foils , 2021, Journal of Radioanalytical and Nuclear Chemistry.

[4]  J. Engle,et al.  Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119. , 2021, Current radiopharmaceuticals.

[5]  D. Filosofov,et al.  Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations. , 2020, Nuclear medicine and biology.

[6]  R. Reilly,et al.  Cellular dosimetry of 197Hg, 197mHg and 111In: comparison of dose deposition and identification of the cell and nuclear membrane as important targets , 2020, International journal of radiation biology.

[7]  O. Lebeda,et al.  Measurement of cross-sections of proton-induced nuclear reactions on 197Au focused on the production of the theranostic pair 197m,gHg , 2019, Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms.

[8]  C. Hoehr,et al.  A Compact Quick-Release Solid Target System for the TRIUMF TR13 Cyclotron , 2019, Instruments.

[9]  A. S. Sobolev,et al.  Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression , 2018, Front. Pharmacol..

[10]  D. Shaughnessy,et al.  Production and isolation of 197m,gHg , 2018, Journal of Radioanalytical and Nuclear Chemistry.

[11]  J. Steinbach,et al.  Theranostic mercury part 1: A new Hg/Au separation by a resin based method , 2017 .

[12]  Julio Caballero,et al.  Direct and Auger Electron-Induced, Single- and Double-Strand Breaks on Plasmid DNA Caused by 99mTc-Labeled Pyrene Derivatives and the Effect of Bonding Distance , 2016, PloS one.

[13]  T. A. Brown,et al.  Production and isolation of homologs of flerovium and element 115 at the Lawrence Livermore National Laboratory Center for Accelerator Mass Spectrometry , 2016, Journal of Radioanalytical and Nuclear Chemistry.

[14]  J. Steinbach,et al.  Theranostic mercury: (197(m))Hg with high specific activity for imaging and therapy. , 2015, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[15]  I. Navarro-Teulon,et al.  Clinical radioimmunotherapy—the role of radiobiology , 2011, Nature Reviews Clinical Oncology.

[16]  R. Macklis,et al.  Review of clinical radioimmunotherapy , 2006, Expert review of anticancer therapy.

[17]  T. Lister,et al.  Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Murray,et al.  Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues. , 2004, Cancer treatment reviews.

[19]  S. Adelstein,et al.  Radiotoxicity of iodine-125 and other auger-electron-emitting radionuclides: background to therapy. , 2003, Cancer biotherapy & radiopharmaceuticals.

[20]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  I. Panyutin,et al.  Radioprobing of DNA: distribution of DNA breaks produced by decay of 125I incorporated into a triplex-forming oligonucleotide correlates with geometry of the triplex. , 1997, Nucleic acids research.

[22]  W. Haseltine,et al.  Range of radiochemical damage to DNA with decay of iodine-125. , 1981, Science.

[23]  Eva Forssell-Aronsson,et al.  Low-energy Electron Emitters for Targeted Radiotherapy of Small Tumours , 2001, Acta oncologica.

[24]  Chunmei Zhou,et al.  Nuclear Data Sheets for A = 197 , 1991 .